ArticleJTO clinical and research reports2026
Patient-Derived Lung Cancer Organoids for Precision Oncology: A Comprehensive Analysis.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to comprehensively assess the accuracy of patient-derived organoids to recapitulate the genomic features of patient tumors, and to quantify the reliability of patient-derived organoid-based drug screening, by pooling the available evidence and the validation using our patient-derived lung cancer organoids (LCOs). Methods: A comprehensive online search was conducted to identify eligible studies. A total of 20 LCOs harvested from surgical samples were also established as our internal validation cohort, with whole-exome sequencing and transcriptomic sequencing performed, respectively. Pooled concordance in genetic profiles between LCOs and original tumors was calculated, along with the overall accuracy of LCOs for drug profiling. Results: The pooled concordance in mutational landscape between LCOs and original tumors reached 74% (95% confidence interval [CI]: 61%-84%) in overall populations without heterogeneity ( Conclusions: Our study indicates that LCOs can stably recapitulate the genomic features of patient tumors irrespective of histologic heterogeneity and be a promising precision medicine tool for anticancer drug screening or for predicting drug responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.